Erectile Dysfunction Treatment Market to Surpass US$ 8.4 Billion by 2027 - Coherent Market Insights

The global erectile dysfunction treatment market, by Product (Viagra (Sildenafil citrate), Cialis(Tadalafil), Stendra/Sperda, Levitra/Staxyn, Zydena (Udenafil), and Vitaros (Alprostadil Cream)), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$  4,946.2 million in 2018, and is expected to exhibit at a CAGR of 6.2% over the forecast period (2019–2027). Frequent product launches and product approvals are expected to drive the global erectile dysfunction treatment market growth over the forecast period Increasing demand for medication to treat erectile dysfunction has led to an increase in product launches by market players, which is expected to drive global erectile dysfunction treatment market growth over the forecast period.

For instance, in September 2019, Lupin Limited launched Sildenafil tablets, USP of 25 mg, 50 mg, and 100 mg, a generic version of Pfizer Inc.’s Viagra tablets. Manufacturers are focused on receiving regulatory approvals for their products. For instance, in March 2019, Alembic Pharmaceuticals received the U.S. Food and Drug Administrational (FDA) approval for Tadalafil tablets that are used in treatment of erectile dysfunction. Moreover, in December 2017, Teva Pharmaceutical Industries Ltd., launched generic version of Viagra (sildenafil citrate) tablets in the U.S., this sildenafil tablets is an affordable generic treatment option for erectile dysfunction. Furthermore, in June 2018, Camber Pharmaceuticals launched generic version of Viagra (sildenafil tablets) indicated for the treatment of erectile dysfunction. Camber Pharmaceuticals generic Viagra are available in 25, 50, and 100 mg dosage strengths.

Browse 33 Market Data, Tables, and 26 Figures spread through 171 Pages and in-depth TOC on The Global Erectile Dysfunction Treatment Market, by Product (Viagra (Sildenafil citrate), Cialis(Tadalafil), Stendra/Sperda, Levitra/Staxyn, Zydena (Udenafil), and Vitaros (Alprostadil Cream), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027

To know the latest trends and insights prevalent in the global erectile dysfunction treatment market, click the link below: https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200

To overcome the barrier in treatment of ED and hesitation among people to discuss about erectile dysfunction, companies are focusing on providing platform for easy availability of the required medicines for people suffering from ED. For instance, in October 2017, Roman (a digital health clinic for men) launched cloud-based pharmacy in California, New York, Florida, and Pennsylvania, especially for people suffering from erectile dysfunction.

Key takeaways:

• The global erectile dysfunction treatment market is expected to exhibit a CAGR of 6.2% during the forecast period (2019–2027), owing to increasing product launch, approval and acquisitions.
• Among region, North America is expected to hold dominant position in global erectile dysfunction treatment market over the forecast period, owing to presence of major key players such as Pfizer Inc, Mylan Pharmaceuticals Inc, and others
• Increasing Prevalence of erectile dysfunction has increased the demand of erectile dysfunction drugs such as Viagra, Cialis and others.
• Some of the major players involved in global erectile dysfunction treatment market include Mylan Pharmaceuticals Inc, Cipla Ltd, Aurobindo Pharma Ltd, Eli Lily & Co, Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG, Dr. Reddys Laboratories Ltd, and Dong-A Pharmaceutical Co., Ltd